EVERY Quadruples OvoPro Capacity Through Huvepharma Partnership
Expansion supports rising demand for precision-fermented egg protein across retail, e-commerce and foodservice channels
The EVERY Company, an organization operating in highly functional egg proteins produced via precision fermentation, announced a significant manufacturing expansion with its strategic partner, Huvepharma, a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The agreement quadruples EVERY’s production capacity to meet high demand for its flagship product, OvoPro, the world’s first commercially available egg protein made via fermentation.
The expansion follows a period of rapid commercial growth for EVERY: in the first four months of 2026, the company secured annual orders worth 550% of its total 2025 order volume. This surge is driven by strong adoption across B2B retail channels, including national placement in Target and Walmart, and to satisfy growing demand across e-commerce and foodservice channels.
Through its subsidiary Biovet AD, Huvepharma will use its world-class fermentation infrastructure in Bulgaria boasting over 9,000,000L of installed fermentation capacity—one of the largest and most flexible in Europe—to facilitate this scale-up. The partnership leverages Biovet’s decades of expertise in large-scale microbial fermentation and downstream processing to ensure consistent, food-grade quality at industrial volumes.
The expanded production will primarily focus on OvoPro, EVERY's pure ovalbumin protein produced through precision fermentation, which delivers performance as both a functional binding agent and a protein-enriching ingredient across baked goods, bars, snacks, confections and pasta. The growing global demand is driven by significant operational and supply chain advantages for the food industry when used as an ingredient: it is shelf-stable for up to 24 months, does not require cold-chain transportation or storage, and offers favorable inclusion economics due to its high purity.
The collaboration has already proven successful at 63,000L industrial scale, and EVERY is now producing at steady state production delivering metric tons to customers regularly. This new phase of expansion will further optimize batch costs and prepare the partnership for future growth as EVERY continues to onboard additional proteins from its fermentation platform.
Looking for a reprint of this article?
From high-res PDFs to custom plaques, order your copy today!
